eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Randomized phase II trial of temsirolimus (NCIi-supplied agent, NSC # 683864, IND # 61010) or the combination of hormonal therapy plus temsirolimus in women with advanced, persistent, or recurrent endometrial carcinoma

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
    Megestrol acetate
  3. Intervention
    Tamoxifen citrate
  4. Intervention
  5. Additional Topic(s)
    Antineoplastic combined chemotherapy protocols
  6. Resource Description
    Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of endometrial cancer cells. Hormone therapy using megestrol and tamoxifen may fight endometrial cancer by blocking the use of estrogen by the tumor cells. It is not yet known whether temsirolimus is more effective when given alone or together with megestrol and tamoxifen in treating endometrial cancer. This randomized phase II trial is studying temsirolimus to see how well it works with or without megestrol and tamoxifen in treating patients with advanced, persistent, or recurrent endometrial cancer.
  7. Contact
    Berenberg, Jeffrey
  8. PI
    Berenberg, Jeffrey
  9. Topic
    endometrial cancer
  10. Study Population
    Females with histologically confirmed endometrial carcinoma.
  11. Website(s)
  12. Funded by
    Gynecologic Oncology Group
  13. Phase
    Phase 2 clinical trial
  14. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016